DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DAPASALT
- Sponsors AstraZeneca
- 09 Sep 2019 Planned End Date changed from 30 Jan 2020 to 30 Apr 2020.
- 09 Sep 2019 Planned primary completion date changed from 30 Jan 2020 to 30 Apr 2020.
- 18 Jul 2019 Planned End Date changed from 20 Dec 2019 to 30 Jan 2020.